pepdex
← Back to index
№ 063

Petrelintide

Novo Nordisk's long-acting amylin analog. Phase 2/3 in development. Successor to Cagrilintide with weekly dosing and improved receptor binding.

Fat Loss
Evidence: Moderate
Half-life
~8 days (pegylated)
Route
Subcutaneous
Cycle
Trial protocols
Schedule
Once weekly
In plain English

Petrelintide is Novo Nordisk's next-generation amylin drug — Cagrilintide's successor. Same pathway as Cagrilintide but with weekly dosing and stronger receptor binding. In Phase 2/3 trials. Will eventually pair with Semaglutide the way CagriSema does, but as one drug.

Status & legality
Natty?
Not natty
FDA
Not approved

Investigational. Phase 2/3 trials by Novo Nordisk. Not yet approved.

Compounding
Investigational

In clinical trials, not yet approved for prescription.

WADA
Not listed
Prescribed

Trial access only.

Who it's for

  • →Trial participants in obesity studies
  • →Educational reference for the next-generation amylin pathway
  • →Followers of Novo's metabolic pipeline

What to expect

  1. Week 1

    Appetite reduction begins. Less GI side effect profile than GLP-1 monotherapy.

  2. Week 4

    First titration step. Weight loss accruing.

  3. Week 8

    Phase 2 endpoint data showed steady cumulative loss.

How it works (mechanism)

Next-generation amylin analog with stronger receptor binding and weekly dosing. Same pathway as Cagrilintide.

Dosing protocol

Start 0.3 mg weekly, titrate over 4-week steps. Trial doses up to 9 mg.

Stacks well with

Standalone in current trials. Eventual pairing with Semaglutide expected (CagriSema-style)

Side effects

01Mild nausea
02Reduced appetite
03Constipation
04Generally cleaner profile than GLP-1 monotherapy

When NOT to use

  • ⚠MTC / MEN-2 history
  • ⚠Pancreatitis history
  • ⚠Pregnancy / nursing

Bloodwork to monitor

  • • Lipid panel
  • • A1C if metabolic context

Common mistakes

  • • Treating community-vendor product as trial-grade material
  • • Titrating too fast
  • • Expecting Tirzepatide-tier weight loss as monotherapy

Drug & supplement interactions

  • ⚠Same amylin-class precaution: oral medication absorption may be affected
  • ⚠Trial-only

Educational only. User-specific dosing is between you and a qualified provider.

Frequently asked

What is Petrelintide?+
Petrelintide is Novo Nordisk's next-generation amylin drug — Cagrilintide's successor. Same pathway as Cagrilintide but with weekly dosing and stronger receptor binding. In Phase 2/3 trials. Will eventually pair with Semaglutide the way CagriSema does, but as one drug.
Is Petrelintide FDA approved?+
Investigational. Phase 2/3 trials by Novo Nordisk. Not yet approved.
Is Petrelintide banned by WADA?+
Petrelintide is not currently on the WADA prohibited list.
Are you still natty after taking Petrelintide?+
No. Petrelintide is a performance-enhancing peptide and would disqualify a strict natty claim.
Do doctors prescribe Petrelintide?+
Trial access only.
What's the typical dose of Petrelintide?+
Start 0.3 mg weekly, titrate over 4-week steps. Trial doses up to 9 mg.
What are the side effects of Petrelintide?+
Common side effects include: Mild nausea; Reduced appetite; Constipation; Generally cleaner profile than GLP-1 monotherapy. Less common effects and full safety details are on the entry page.
How long until Petrelintide starts working?+
Appetite reduction begins. Less GI side effect profile than GLP-1 monotherapy.

More in Fat Loss

№ 008
Tirzepatide

Dual agonist (GLP-1 + GIP). FDA-approved as Mounjaro / Zepbound. Strong weight loss with cleaner side effect profile than semaglutide.

№ 009
Semaglutide

GLP-1 agonist. The original wave. Sold as Ozempic / Wegovy.

№ 003
Retatrutide

Triple agonist (GLP-1 + GIP + glucagon) from Eli Lilly. In trials it outperforms Tirzepatide for weight loss.

№ 058
Liraglutide (Saxenda / Victoza)

Daily GLP-1 receptor agonist. FDA-approved 2010 (Victoza, T2D) and 2014 (Saxenda, obesity). The first wave of modern GLP-1 weight-loss therapy and direct predecessor to Semaglutide.